Last updated on March 2018

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma


Brief description of study

A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Detailed Study Description

This is a Phase Ib and II open-label, multi-center study to evaluate the safety, tolerability, pharmacodynamics, and antitumor activity of MEDI4736 in combination with chemotherapy or AZD5069 in patients with pancreatic ductal adenocarcinoma (PDAC). This study will consist of 2 independent cohorts.

Clinical Study Identifier: NCT02583477

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
Stanford, CA United States

AstraZeneca Clinical Study Information Center

Research Site
Rochester, NY United States

AstraZeneca Clinical Study Information Center

Research Site
Pittsburgh, PA United States

AstraZeneca Clinical Study Information Center

Research Site
Bebington, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Cambridge, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Glasgow, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
London, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Manchester, United Kingdom